الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 85 |  |  |
| | | from | 85 | | |
Abstract
The present study was undertaken to evaluate the impact of chrysanthemum on
genotoxicity as well as renal & hepatic toxicity in the anticancer drug
Capecitabine (xeloda) exposed male rats using comet assay and biochemical
alterations. Thirty six male albino rat were divided into 6 groups (6 animals
each) as follows:1) capecitabine (xeloda at dose of 30 mg as appositive control);
2) capecitabine (xeloda) + low dose of chrysanthemum (5 mg); 3) capecitabine
(xeloda) + high dose of chrysanthemum (10 mg) ); 4) chrysanthemum (low
dose, 5 mg) 5) chrysanthemum ( high dose, 10 mg); 6) Control group (negative
control) for 45 days. The results of the present study revealed that capecitabine
(xeloda) induced high frequency of DNA damage showed by alteration in tail
length, tail moment, and DNA in tail. However, the treatment with
Chrysanthemum significantly reduced the frequent of these parameters. The
biochemical findings indicate that capecitabine (xeloda) treatment induce
biochemical changes in hematological parameters, liver and kidney function,
however the treatment with capecitabine (xeloda) in combination with
Chrysanthemum ameliorate these changes especially with the high dose of
Chrysanthemum. In conclusion, the data suggest that the complimentary use of
Chrysanthemum with capecitabine (xeloda) treatment will be beneficial to
reduce the adverse effect of capecitabine (xeloda) in chemotherapy, including
the increased incidence of undesirable mutagenic and biochemical side effects.